XML 23 R7.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)
shares in Millions, $ in Millions
Total
Total CVS Health Shareholders’ Equity
Common Shares
Treasury Shares
Common Stock and Capital Surplus
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Noncontrolling Interests
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2023     1,768          
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2023 [1]       (480)        
Balance at beginning of period at Dec. 31, 2023 $ 76,636 $ 76,461   $ (33,838) [1] $ 48,992 [2] $ 61,604 $ (297) $ 175
Shareholders' Equity [Roll Forward]                
Net income 1,124 1,113       1,113   11
Other comprehensive income (loss) (44) (44)         (44)  
Stock option activity, stock awards and other (in shares)     3          
Stock option activity, stock awards and other 244 244     244 [2]      
Purchases of treasury shares, net of ESPP issuances (in shares) [1]       (39)        
Purchase of treasury shares, net of ESPP issuances (2,962) (2,962)   $ (2,935) [1] (27) [2]      
Common stock dividends (844) (844)       (844)    
Other increases (decreases) in noncontrolling interests (4) 0           (4)
Shares outstanding, balance at end of period (in shares) at Mar. 31, 2024     1,771          
Treasury shares outstanding, balance at end of period (in shares) at Mar. 31, 2024 [1]       (519)        
Balance at end of period at Mar. 31, 2024 $ 74,150 73,968   $ (36,773) [1] 49,209 [2] 61,873 (341) 182
Shareholders' Equity [Roll Forward]                
Dividends declared per share (in dollars per share) $ 0.665              
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2023     1,768          
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2023 [1]       (480)        
Balance at beginning of period at Dec. 31, 2023 $ 76,636 76,461   $ (33,838) [1] 48,992 [2] 61,604 (297) 175
Shareholders' Equity [Roll Forward]                
Net income 2,892              
Other comprehensive income (loss) (22)              
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2024     1,777          
Treasury shares outstanding, balance at end of period (in shares) at Jun. 30, 2024 [1]       (521)        
Balance at end of period at Jun. 30, 2024 $ 75,111 74,930   $ (36,919) [1] 49,371 [2] 62,797 (319) 181
Shareholders' Equity [Roll Forward]                
Dividends declared per share (in dollars per share) $ 1.33              
Shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2024     1,771          
Treasury shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2024 [1]       (519)        
Balance at beginning of period at Mar. 31, 2024 $ 74,150 73,968   $ (36,773) [1] 49,209 [2] 61,873 (341) 182
Shareholders' Equity [Roll Forward]                
Net income 1,768 1,770       1,770   (2)
Other comprehensive income (loss) 22 22         22  
Stock option activity, stock awards and other (in shares)     6          
Stock option activity, stock awards and other 159 159     159 [2]      
Purchases of treasury shares, net of ESPP issuances (in shares) [1]       (2)        
Purchase of treasury shares, net of ESPP issuances (143) (143)   $ (146) [1] 3 [2]      
Common stock dividends (846) (846)       (846)    
Other increases (decreases) in noncontrolling interests 1 0           1
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2024     1,777          
Treasury shares outstanding, balance at end of period (in shares) at Jun. 30, 2024 [1]       (521)        
Balance at end of period at Jun. 30, 2024 $ 75,111 74,930   $ (36,919) [1] 49,371 [2] 62,797 (319) 181
Shareholders' Equity [Roll Forward]                
Dividends declared per share (in dollars per share) $ 0.665              
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2024     1,778          
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2024 (518)     (518) [3]        
Balance at beginning of period at Dec. 31, 2024 $ 75,730 75,560   $ (36,818) [3] 49,661 [4] 62,837 (120) 170
Shareholders' Equity [Roll Forward]                
Net income 1,782 1,779       1,779   3
Other comprehensive income (loss) 179 179         179  
Stock option activity, stock awards and other (in shares)     1          
Stock option activity, stock awards and other 176 176     176 [4]      
ESPP issuances, net of purchase of treasury shares (in shares) [3]       1        
ESPP issuances, net of purchase of treasury shares 83 83   $ 83 [3]        
Common stock dividends (848) (848)       (848)    
Other increases (decreases) in noncontrolling interests 8 0           8
Shares outstanding, balance at end of period (in shares) at Mar. 31, 2025     1,779          
Treasury shares outstanding, balance at end of period (in shares) at Mar. 31, 2025 [3]       (517)        
Balance at end of period at Mar. 31, 2025 $ 77,110 76,929   $ (36,735) [3] 49,837 [4] 63,768 59 181
Shareholders' Equity [Roll Forward]                
Dividends declared per share (in dollars per share) $ 0.665              
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2024     1,778          
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2024 (518)     (518) [3]        
Balance at beginning of period at Dec. 31, 2024 $ 75,730 75,560   $ (36,818) [3] 49,661 [4] 62,837 (120) 170
Shareholders' Equity [Roll Forward]                
Net income 2,795              
Other comprehensive income (loss) $ 392              
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2025     1,785          
Treasury shares outstanding, balance at end of period (in shares) at Jun. 30, 2025 (518)     (518) [3]        
Balance at end of period at Jun. 30, 2025 $ 77,551 77,379   $ (36,849) [3] 50,020 [4] 63,936 272 172
Shareholders' Equity [Roll Forward]                
Dividends declared per share (in dollars per share) $ 1.33              
Shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2025     1,779          
Treasury shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2025 [3]       (517)        
Balance at beginning of period at Mar. 31, 2025 $ 77,110 76,929   $ (36,735) [3] 49,837 [4] 63,768 59 181
Shareholders' Equity [Roll Forward]                
Net income 1,013 1,021       1,021   (8)
Other comprehensive income (loss) 213 213         213  
Stock option activity, stock awards and other (in shares)     6          
Stock option activity, stock awards and other 183 183     183 [4]      
Purchases of treasury shares, net of ESPP issuances (in shares) [3]       (1)        
Purchase of treasury shares, net of ESPP issuances (114) (114)   $ (114) [3]        
Common stock dividends (853) (853)       (853)    
Other increases (decreases) in noncontrolling interests $ (1) 0           (1)
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2025     1,785          
Treasury shares outstanding, balance at end of period (in shares) at Jun. 30, 2025 (518)     (518) [3]        
Balance at end of period at Jun. 30, 2025 $ 77,551 $ 77,379   $ (36,849) [3] $ 50,020 [4] $ 63,936 $ 272 $ 172
Shareholders' Equity [Roll Forward]                
Dividends declared per share (in dollars per share) $ 0.665              
[1] Treasury shares include 1 million shares held in trust and treasury stock includes $29 million related to shares held in trust as of June 30, 2024, March 31, 2024 and December 31, 2023.
[2] Common stock and capital surplus includes the par value of common stock of $18 million as of June 30, 2024, March 31, 2024 and December 31, 2023.
[3] Treasury shares include 1 million shares held in trust and treasury stock includes $29 million related to shares held in trust as of June 30, 2025, March 31, 2025 and December 31, 2024.
[4] Common stock and capital surplus includes the par value of common stock of $18 million as of June 30, 2025, March 31, 2025 and December 31, 2024.